Skip to main content
Premium Trial:

Request an Annual Quote

Daniel Bradbury, Frank Karbe, George Scangos, Paul Bunn, Theodore Friedmann, Susan Gross, Stephen Morse, Osagie Imasogie, Andy Morffew, Scott Clarke, Beth Kennedy, David Lawrence

Premium

Daniel Bradbury has joined the board of directors of San Diego-based Illumina. Bradbury is currently the chief operating officer of Amylin Pharmaceuticals and is on the board of directors of Peninsula Pharmaceuticals. Bradbury holds a pharmacy degree from Nottingham University and a diploma in management studies from Harrow and Ealing College of Higher Education (UK).


Frank Karbe joins South San Francisco-based Exelixis as senior vice president and chief financial officer, the company said this week. He will report directly to George Scangos, president and chief executive officer. Previously, Karbe was vice president in the healthcare group of Goldman Sachs and has experience in the areas of mergers and acquisitions and corporate finance. He holds the German equivalent of an MBA from the Otto Beisheim Graduate School of Management in Koblenz, Germany.


Boulder, Colo-based NaPro BioTherapeutics this week announced that Paul Bunn, Theodore Friedmann, Susan Gross, and Stephen Morse have joined its scientific advisory board.

Bunn is currently the director of the University of Colorado Cancer Center and has a research speciality in lung cancer. Friedmann is a professor of pediatrics and director of the gene therapy program at the University of California, San Diego. Gross is co-director of the division of reproductive genetics at Montefiore Medical Center and Albert Einstein College of Medicine. Morse is director of the center for public health and associate professor of clinical epidemiology at Columbia University’s Mailman School of Public Health, and is a former program manager at the Defense Advanced Research Projects Agency.


Osagie Imasogie joins the board of directors of Genaera, the company said this week. Osagie served as the founder and vice president of GlaxoSmithKline Ventures, GSK’s Intellectual Property Venture Capital Group. He has served in senior executive positions within GlaxoSmithKline, SmithKline Beecham, Endo Pharmaceuticals, DuPont Merck Pharmaceutical, and Price Waterhouse.


Andy Morffew joins Cambridge, UK-based Automation Partnership as chief executive, succeeding Richard Archer who is retiring in February, the company said. Previously, Morffew was president of the consulting group of the contract research organization, Parexel. Prior to that, he led IBM’s European Pharmaceutical and Process Industries practice. The Automation Partnership designs and develops advanced industrial automation solutions for life science industries.


Scott Clarke has been appointed president and CEO of Discovery Innovations, a new web-based informatics spinoff of BioSpace, where he was president and CEO. Other BioSpace executives will go to Discovery Innovations, including Beth Kennedy, executive vice president, who formerly worked as an IT manager at Incyte.


David Lawrence has become an advisor to the board of directors of SomaLogic. Until 2002, he was CEO and chairman of the board of Kaiser Foundation Health Plan and Kaiser Foundation Hospitals.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.